Statement of Vascular Solutions on Grand Jury Indictment

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Statement of Vascular Solutions on Grand Jury Indictment

MINNEAPOLIS, Nov. 13, 2014 (GLOBE NEWSWIRE) -- In response to an indictment returned today by a federal grand jury in the Western District of Texas, Vascular Solutions, Inc. (Nasdaq: VASC ) issued the following statement:

"The allegations against us are false and we will contest them vigorously. The indictment is the profoundly flawed product of government attorneys who have conducted a misguided and abusive investigation. Without the company being able to present any information to the grand jury, today's action is not surprising. It is, however, fundamentally wrong and profoundly unjust.

"As previously disclosed, the U.S. Attorney's Office in San Antonio and the Consumer Protection Branch of the Department of Justice conducted a four-year investigation concerning the since-discontinued Short Kit version of our Vari-Lase product for the treatment of varicose veins in the leg. That investigation led to today's indictment, which alleges that members of Vascular Solutions' sales force spoke to physicians about the use of the Short Kit to treat varicose perforator veins in the leg. The indictment further alleges that the treatment of a leg's perforator veins, as opposed to the more-commonly treated saphenous veins, is outside the Short Kit's labeled indications and therefore constitutes an 'off-label' use.

"We vehemently disagree with both allegations: we did not engage in any illegal off-label promotion of the Short Kit, nor did we engage in any false or misleading conduct.

"Sales of the Short Kit for all clinical uses during the seven years it was on the U.S. market were $534,000, representing just 0.1% of our total U.S. sales during those years. Over two-thirds of our sales representatives never sold even a single Short Kit, and the Short Kit has never been the subject of any reported serious adverse event in any patient.

"The discrepancy between the insignificance of our Short Kit product and the severity of the government's actions in this matter is simply astonishing. The reason for that discrepancy will become readily apparent when the government attorneys' stated motives and abusive conduct in this investigation are disclosed in our upcoming court filings.

"We cooperated fully during the government's investigation and pointed out the flaws in the government's theories and evidentiary assumptions. While confident in our innocence, in order to avoid the costs and distractions of this matter we tried repeatedly to find a reasonable resolution, just as we achieved with the related civil lawsuit that settled earlier this year, but to no avail.

"We will defend our company and our employees against these improper and false allegations through trial where we are confident of prevailing. We have the resources to vigorously contest the allegations and an excellent legal team in place.

"While proceeding with our legal defense, we plan to make no change to our business operations or personnel as a result of this matter."

John Erb, Chairman of the Board of Vascular Solutions, added the following statement:

"I have led the independent members of the Board of Directors in providing active direction to and oversight of the company's response to this investigation. The Board of Directors unanimously supports management's handling of this matter and the company's defense against these unwarranted charges. The Board of Directors has determined that it is appropriate and in the best interests of Vascular Solutions that Howard Root continue as CEO throughout this legal process and to its successful resolution at trial.

"To put this matter into perspective, since its inception in 1997, Vascular Solutions has created over 450 well-paid American jobs and developed over 80 new medical devices that improve patients' lives. The company has a complete and detailed compliance program, and this matter is the only allegation of a sales promotion issue that the company has received in its 17-year history. In that context, today's indictment is both disproportionate and unjust."

A grand jury indictment is not a verdict or finding of guilt, but rather a determination of whether a crime should be charged. Only the prosecuting attorney is allowed to present evidence to the grand jury, and no judge or defense attorney is present during the grand jury sessions. The validity of the charges included in the indictment is determined only by a jury following trial. 

Background

The Vari-Lase Short Kit was sold in the U.S. from October 2007 through July 2014 under an FDA 510(k) clearance for the treatment of varicose veins and varicosities associated with superficial reflux of the great saphenous vein and for treatment of incompetence and reflux of superficial veins in the lower extremity.

The criminal investigation is related to a qui tam "whistle-blower" civil lawsuit filed in 2010. The U.S. Attorney's office for the Western District of Texas intervened in the civil lawsuit, in part, in 2012. On January 22, 2014, the company reached an agreement with the Department of Justice to settle the civil lawsuit, and a settlement agreement was fully executed on July 28, 2014. Under the terms of that agreement, the company paid $520,000 with no admission of fault or liability, and the U.S. Attorney's office supported dismissal of the civil lawsuit with prejudice and released all civil claims brought against the company in the civil lawsuit. As previously disclosed, the settlement of the civil lawsuit had no effect upon the criminal investigation.

The indictment returned today by a federal grand jury in the Western District of Texas charges Vascular Solutions and its Chief Executive Officer with introducing adulterated and misbranded medical devices into interstate commerce and conspiracy to introduce adulterated and misbranded medical devices into interstate commerce.

As has been previously disclosed, conviction of the company of a crime under statutes related to fraud could result in the company's exclusion from participation in all U.S. government health care programs including Medicare and Medicaid, which would substantially adversely affect the company's ability to continue to conduct its business. Conviction of an employee of a crime under statutes related to misbranding and health care fraud could result in termination of the employee's employment with the company and prohibition from employment with any health care company that contracts with the federal government.

Additional information concerning this matter is included in a Form 8-K report filed today with the Securities and Exchange Commission and available on the SEC website.

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of more than 80 products and services in three categories: catheter products, hemostat products and vein products. Vascular Solutions delivers its products and services to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.

For further information on Vascular Solutions, connect to www.vasc.com .

Investors: Phil Nalbone VP of Vascular Solutions (763) 656-4371 Media: Jon Austin J Austin & Associates (612) 839-5172

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 58

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 85

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 152

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 103

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 70

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 30

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 85

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading

Top 5 Most Recently Viewed Articles

Penske's Q3 2026: Revenue Up, Private Deal Awaits

Updated Category News Views 189

Jumping straight into it, Penske Automotive Group (NYSE: PAG) just rolled out their quarterly numbers. The highlights? A 5% revenue bump, landing at $8.4 billion. That's nice, sure, but let's not get too cozy, there's a bigger elephant in this garage—it's the bold move to take the company private! Our old friend volatility still sends shivers down the spine of long-time...

Continue Reading
Shanghai Hosts 20th Global Entrepreneurship Week

Updated Category News Views 226

Shanghai: A Hacker's Paradise of Innovation? The heart of financial ambition beats loud and clear in Shanghai this time of year. November 10 to 14, 2026, promises to be a spectacle of entrepreneurial valor as the city hosts the 20th Global Entrepreneurship Week China. This isn't just some run-of-the-mill networking shindig; we're talking about over 50 dazzling events,...

Continue Reading
Strategic Merger of BerGenBio and Oncoinvent Bolsters Growth

Updated Category News Views 247

BerGenBio and Oncoinvent Proposed Merger Overview In a significant development within the biotechnology sector, BerGenBio ASA and Oncoinvent ASA have announced their plans for a merger. The merger aims to combine both companies into a single entity with BerGenBio as the acquiring company, fostering a collaborative approach to advancing innovative cancer therapies. Details...

Continue Reading
Cloud-Native Application Protection Platform Market Sees Surge

Updated Category News Views 89

Cloud-Native Application Protection Platform Market Surge The Cloud-Native Application Protection Platform (CNAPP) market is witnessing remarkable growth, recently reported to be nearly $700 million in the second quarter of 2024. This represents a staggering 42 percent increase year-over-year. The recent findings emphasize how companies are prioritizing cloud security as...

Continue Reading
Arkay Zero Proof's Bold Move with $6 Million Times Square Launch

Updated Category News Views 319

Arkay Zero Proof Takes Times Square by Storm with Major Campaign Arkay Zero Proof, known for its innovative non-alcoholic spirits, is making headlines with a bold advertising initiative in the bustling Times Square. With a remarkable investment of $6 million, this campaign aims to enhance Arkay's brand visibility while reinforcing its position in the thriving market of...

Continue Reading